

### **DECEMBER 10-13, 2024**

HENRY B. GONZALEZ CONVENTION CENTER • SAN ANTONIO, TX

### **Program**

[Last updated: September 26, 2024]

### Tuesday, December 10 (All times are in CST)

12:00 – 1:30 pm Prevention Special Session: Mechanisms of Obesity Related Risk for Breast Cancer and Approaches to Risk Reduction

Moderator: Carol Fabian, University of Kansas Medical Center, Westwood, Kansas

- Lifestyle, Genetic, and Epigenetic Interactions in Predicting Development of Obesity and Response to Calorie Restriction and Physical Activity Speaker to be announced
- Achieving Sufficient Fat loss and Metabolic Improvement to Reduce Cancer Risk: Newer Generation GLP-1n and GIP Receptor Agonists (Nutrient Sensing Hormone (NUSH) - Based Therapeutics Robert Kushner, Northwestern University Feinberg School of Medicine, Chicago, Illinois
- Impact and Types of Exercise and Pharmacotherapy in Weight Loss **John Jakicic,** University of Kansas Medical Center, Westwood, Kansas
- Panel Discussion

12:00 – 1:45 pm FDA Special Session: New Drug Approvals

12:00 – 1:45 pm Special Session 3: Sex, Drugs, Rock & Roll

Moderator: Christine Ambrosone, Roswell Park Comprehensive Cancer Center,

Buffalo, New York

Patient Advocate: Tomika Bryant

Supplements and Cannabis

Heather Greenlee, Fred Hutch Cancer Center, Seattle, Washington

Sexual Health

**Don Dizon,** Legorreta Cancer Center at Brown University/Lifespan Cancer Institute, Providence, Rhode Island

• Exercise During Treatment

**Rikki Cannioto,** Roswell Park Comprehensive Cancer Center, Buffalo, New York

Alcohol

**Marilyn Kwan,** Kaiser Permanente Northern California, Pleasanton, California

Panel Discussion

2:00 – 3:45 pm Clinical Workshop: Dose Optimization in Breast Medical Oncology

# 2:00 – 3:45 pm Translational Workshop: Cancer Immunology Discovery Approaches into Clinical Trials

Moderator: Christine Desmedt, KU Leuven, Leuven, Belgium

- Multiplex Imaging for Precision Oncology
   Raza Ali, Cancer Research UK, Cambridge, United Kingdom
- Single Cell T-Cell Receptors and B-Cell Receptors

  Diether Lambrechts, Catholic University of Leuven, Leuven, Belgium
- Spatial Transcriptomics
   Christos Sotiriou, Institut Jules Bordet, Brussels, Belgium
- Cancer Immunology Discovery Approaches into Clinical Trials
   Emanuela Romano, Institut Curie, Paris, France
- Panel Discussion

#### 4:00 – 4:30 pm Review of Current Technologies

#### 4:00 – 4:30 pm Therapy Induced Evolution

#### 4:00 – 4:30 pm **Neoadjuvant Management and Adaptive Strategies**

#### 4:00 – 5:45 pm Educational Session 1: Mind the Gap—Breast Cancer in the Young

Moderator: Matteo Lambertini, University of Genova - IRCCS Ospedale Policlinico

San Martino, Genoa, Italy

Patient Advocate: Na'Diah Smith

- Biology of Breast Cancer in Young Women
   Camila Dos Santos, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York
- Ovarian Suppression: Who, When, Why, and for How Long
   Prudence Francis, Peter MacCallum Cancer Centre, Melbourne, Australia
- Survivorship Jennifer Sheng, Johns Hopkins University, Baltimore, Maryland
- Panel Discussion

## 4:00 – 5:45 pm Educational Session 2: Liquid Biopsy: MRD, CT DNA, and Monitoring Response to Treatment

Moderator: Adrian Lee, University of Pittsburgh, Pittsburgh, Pennsylvania

- Patient Advocate: Ellen Landsberger

   Review of Current Technologies
  - Heather Parsons, Dana-Farber Cancer Institute, Boston, Massachusetts
    Early Detection and Molecular Recurrent Disease
  - Ben Park, Vanderbilt University Medical Center, Nashville, Tennessee
  - Utility in the Metastatic Setting
     David Cescon, UHN Princess Margaret Cancer Centre, Toronto, Canada
  - Panel Discussion

4:00 – 5:45 pm

#### **Educational Session 3: Tumor Heterogeneity and Evolution**

Moderator: Reuben S. Harris, UT Health San Antonio, San Antonio, Texas

- Therapy Induced Evolution
  - Nicholas Navin, UT MD Anderson Cancer Center, Houston, Texas
- Genomic and Microenvironment Determinants of Breast Cancer Progression
  - Christina Curtis, Stanford University, Stanford, California
- Single Cell Genomics in Triple Negative Breast Cancer
   Ashley Laughney, Weill Cornell Medicine, New York, New York
- Panel Discussion

4:00 – 5:45 pm

## **Educational Session 4: Optimizing Early HER2 Positive Breast Cancer Treatment**

Moderator: Javier Cortes, International Breast Cancer Center, Barcelona, Spain

- Neoadjuvant Management and Adaptive Strategies
   Gabe Sonke, Netherlands Cancer Institute, Amsterdam, Netherlands
- Treatment of Small Tumors in Early-Stage Setting
   Adrienne Waks, Dana-Farber Cancer Institute, Boston, Massachusetts
- Post Neoadjuvant Management for non pCR
   Joyce O'Shaughnessy, Baylor University, Dallas, Texas
- Panel Discussion

5:45 – 6:15 pm

**Refreshment and Networking Break** 

6:15 – 7:00 pm

**Late Breaking Oral Presentations** 

### Wednesday, December 11 (All times are in CST)

7:00 – 8:30 am	Concurrent Poster Spotlight Sessions 1-5
8:30 – 9:00 am	Welcome and Opening Remarks
9:00 – 9:30 am	William L. McGuire Memorial Lecture
9:30 – 11:45 am	General Session 1
12:00 – 12:50 pm	Rapid Fire 1
12:00 – 2:00 pm	Poster Session 1
12:00 – 1:45 pm	<ul> <li>Early Detection</li> <li>Moderator: Ismail Jatoi, UT Health San Antonio Mays Cancer Center, San Antonio, Texas</li> <li>Risk-Based Screening in the Average Population         Karla Kerlikowske, University of California San Francisco, San Francisco, California</li> <li>Novel Imaging Modalities         Connie Lehman, Harvard Medical School and Massachusetts General Hospital, Boston, Massachusetts</li> <li>Screening for High-Risk Women         Speaker to be announced</li> <li>Panel Discussion</li> </ul>
1:00 – 1:50 pm	Clinical Case Discussions
2:00 – 3:00 pm	State of the Art Session 1: The Winding Road of Immune Biomarkers in Early Breast Cancer  Moderator: Sherene Loi, Peter MacCallum Cancer Centre, Melbourne, Australia  TILs: An Update After 10 Years of Research Roberto Salgado, Peter MacCallum Cancer Centre, Melbourne, Australia Immune Biomarkers Beyond TILs

- Immune Biomarkers Beyond TILs
  - **Justin Balko,** Vanderbilt-Ingram Cancer Center, Nashville, Tennessee
- Deploying Immune Biomarkers in Clinical Trials
   Priyanka Sharma, University of Kansas Medical Center, Westwood, Kansas
- Panel Discussion

#### 2:00 – 3:00 pm Clinical Controversies

# Omission of Axillary Staging in ER Positive Breast Cancer: Implications on Adjuvant Therapies

Monica Morrow, Memorial Sloan Kettering Cancer Center, New York, New York

- Omission of Axillary Staging in ER+ Disease What is The Data?
   Elizabeth Mittendorf, Dana-Farber Cancer Institute, Boston,
   Massachusetts
- Omission of Axillary Staging in ER+ Disease Implications for Radiotherapy Speaker to be announced
- Omission of Axillary Staging in ER+ Disease: Implications for Adjuvant Systemic Therapy

Kevin Kalinsky, Emory Winship Cancer Institute, Atlanta, Georgia

- Radiation Post pCR
  - **Richard Zellars,** Indiana University School of Medicine, Indianapolis, Indiana
- Panel Discussion

#### 3:30 - 5:15 pm

#### **Educational Session 5: Unlocking New Targets with Molecular Degraders**

Speakers to be announced

- PROTACs
- Lysosome-targeting Chimeras
- Biparatropic Antibodies
- Panel Discussion

#### 3:30 – 5:15 pm

# **Educational Session 6: Case Based Clinical Approach to ER Positive Metastatic Breast Cancer**

Moderator: Sarah Hurvitz, Fred Hutch Cancer Center, Seattle, Washington Patient Advocate: Amy Beumer

- PI3Kinase/AKT Pathway Targeting
- ESR1 Mutations
- CDK4/6 Resistance Genomics
- When to Rebiopsy Tissue vs Liquid Biopsy
- Single Agent Hormonal Therapy Sonia Data
- Panel Discussion

**Michael Oliphant,** Harvard Medical School, Boston, Massachusetts **Aditya Bardia,** UCLA David Geffen School of Medicine, Los Angeles, California

**Neil Vasan,** Columbia University Irving Medical Center, New York, New York

**Dan Stover,** The Ohio State University Comprehensive Cancer Center, Columbus, Ohio

#### 3:30 - 5:15 pm

#### **Educational Session 7: The Best of AACR**

Speakers to be announced

#### 3:30 – 5:15 pm Educational Session 8: Optimizing Local Therapy

Moderator: Tari King, Dana-Farber Brigham Cancer Center, Boston,

Massachusetts

Patient Advocate: Yvonne Florance

• Let's Talk About PBI

Atif Khan, Memorial Sloan Kettering Cancer Center, New York, New York

 Axillary Management: When to Dissect and When to Radiate
 Stephanie Wong, Jewish General Hospital Segal Cancer Centre, McGill University Medical School, Montreal, Canada

Surgical Prevention and Management of Lymphedema
 Sarah McLaughlin, Mayo Clinic, Jacksonville, Florida

• Panel Discussion

### Thursday, December 12 (All times are in CST)

7:00 – 8:30 am **Concurrent Poster Spotlight Sessions 6-10** 8:30 – 9:00 am **Plenary Lecture** The Grand Challenge of Unraveling Social vs Biological Drivers of Racial Disparities in Cancer Outcomes Melissa B. Davis, Morehouse School of Medicine, Atlanta, Georgia 9:00 – 11:45 am **General Session 2 Poster Session 3** 12:00 -2:00 pm 12:00 – 12:50 pm Rapid Fire 2 12:30 – 1:45 pm The Future of Cancer Genetics Is Here Moderator: Claudine Isaaks, Georgetown University, Washington, DC

Patient Advocate: Tanja Spanic, Europa Donna Slovenia, Ljubljana, Slovenia

 Saturation Genome Editing-Based Functional and Clinical Classification of VUS in BRCA2

Fergus Couch, Mayo Clinic, Rochester, Minnesota

- Updates on Risk Prediction Models Antonis Antoniou, Cancer Research UK Cambridge Center, Cambridge, United Kingdom
- Reversion Mutations in BRCA1/2 in Response to Therapy Katherine Nathanson, University of Pennsylvania Abramson Cancer Center, Philadelphia, Pennsylvania
- Panel Discussion

#### 1:00 – 1:50 pm **Molecular Tumor Board**

- Jorge Reis-Filho, AstraZeneca, Gaithersburg, Maryland
- Philippe Bedard, Princess Margaret Cancer Centre, Toronto, Canada
- Jenna Canzoniero, Johns Hopkins Sidney Kimmel Cancer Center, Baltimore, Maryland
- Bob Riter, Cornell University, Ithaca, New York

#### 2:00 – 3:00 pm **Translational Controversies**

- How to Define Triple Negative Breast Cancer Rebecca Dent, National Cancer Center Singapore, Singapore Charles Perou, UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina
- Tumor Agnostic Drug Development Funda Meric, MD Anderson Cancer Center, Houston, Texas Fabrice Andre, Institut Gustave Roussy, Villejuif, France

#### 2:00 - 3:00 pm

# **State of the Art: Revolutionizing Diagnosis and Discovery with Artificial Intelligence**

Moderator: Fred Howard, University of Chicago, Chicago, Illinois

- Pathology
  - Speaker to be announced
- Imaging and Screening
  - Ritse Mann, Netherlands Cancer Institute, Amsterdam, Netherlands
- Drug Discovery, Deep Learning, and Large Data Management Speaker to be announced
- Panel Discussion

#### 3:30 – 5:15 pm

#### **Educational Session 9: Artificial Intelligence in the Clinic**

Moderator: Debra Patt, Texas Oncology-Austin Central, Austin, Texas

Patient Advocate: Kay Firth-Butterfield

Hazards and Opportunities

Andrew Hantel, Dana-Faber Cancer Institute, Boston, Massachusetts

- Beyond Chat GPT: Generative AI in Healthcare Speaker to be announced
- Digital Tools for Clinical Practice
   Emily Ray, UNC Lineberger Comprehensive Cancer Center, Chapel Hill,
   North Carolina
- Panel Discussion

#### 3:30 – 5:15 pm

#### **Educational Session 10: Immunotherapy**

Moderator: Heather McArthur, UT Southwestern Medical Center, Dallas, Texas

- Immunotherapy in Early ER Positive Breast Cancer
  - Cesar Santa Maria, John Hopkins Medicine, Baltimore, Maryland
- Optimization of Treatment in TNBC
  - Marleen Kok, Netherlands Cancer Institute, Amsterdam, Netherlands
- The Future of Immunotherapy
  - **Evanthia Roussos Torres,** University of Southern California, Los Angeles, California
- Panel Discussion

#### 3:30 - 5:15 pm

#### **Educational Session 11: Mind the Gap—Breast Cancer in Older Adults**

Moderator to be announced

Patient Advocate: Sandi Stanford

- The Aging Immune System with Hormonal Changes Speaker to be announced
- Defining and Avoiding Low Value Surgical Therapy
   Christina Minami, Brigham and Women's Hospital, New York, New York
- Systemic Therapies
  - Hans Wildiers, University Hospital Leuven, Leuven, Belgium
- Panel Discussion

3:30 – 5:15 pm Educational Session 12: The Biology and Treatment Implications of Organ Specific Metastases

Moderator: Heide Ford, University of Colorado Denver School of Medicine,

Denver, Colorado

Patient Advocate: Christine Hodgdon, Sidney Kimmel Comprehensive Cancer

Center, Baltimore, Maryland

• Brain Metastases

**Diana Cittelly,** University of Colorado Anschutz Medical Campus, Aurora, Colorado

Liver Metastases

Peter Vermeulen, GZA Hospital Sint-Augustinus, Antwerp, Belgium

• Bone Metastases

Rachelle Johnson, Vanderbilt University Medical Center, Nashville

Tennessee

• Panel Discussion

5:30 – 7:00 pm **Poster Session 4** 

8:00 – 10:30 pm SABCS Celebration

### Friday, December 13 (all times are in CST)

7:00 – 8:30 am **Concurrent Poster Spotlight Sessions 11-15** 8:30 – 9:00 am **Plenary Lecture** Cell Atlases as Roadmaps in Cancer Immunology Walid Khaled, University of Cambridge, Cambridge, United Kingdom 9:00 – 11:45 am **General Session 3 Poster Session 5** 12:00 -2:00 pm 12:30 – 1:45 pm

**New Directions in Breast Cancer Prevention** 

Moderator: Gretchen Benson, National Cancer Institute, Bethesda, Maryland

- Prevention Vaccines: Where Are We Now and Where Are We Going? Olivera Finn, University of Pittsburgh, Pittsburgh, Pennsylvania
- Can We Use Biomarkers to Implement Prevention? Seema Khan, Feinberg School of Medicine of Northwestern University, Chicago, Illinois
- From Bench to Clinical Trial: A New Target for Breast Cancer Prevention Geoff Lindeman, Walter and Eliza Hall Institute of Medical Research, Parkville, Australia
- Panel Discussion

Debate: All Patients Should be Offered Universal Germline Genetic Testing 2:00 - 2:50 pm

Moderator: Virginia Kaklamani, UT Health San Antonio, San Antonio, Texas

- Opening Remarks and Polling
- Debate For

Allison Kurian, Stanford University, Stanford, California

- Debate Against
  - Raymond Kim, UHN Princess Margaret Cancer Centre, Toronto, Canada
- Closing Remarks and Polling

3:00 - 5:00 pm **Year in Review** 

> Moderators: Carlos Arteaga, UT Southwestern Medical Center, Dallas, Texas; and Virginia Kaklamani, UT Health San Antonio, San Antonio, Texas

- Translational Science Updates
  - Pedram Razavi, Memorial Sloan Kettering Cancer Center, New York, New York
- Early Breast Cancer Updates Speaker to be announced
- Advanced Breast Cancer Updates Michael Danso, Virginia Oncology Associates, Norfolk, Virginia Basic Science
- **Neil Vasan, Columbia University, New York, New York**

5:00 – 5:30 pm **Reception Break** 

**View from the Trenches** 5:30 – 7:00 pm